No quarterly revenue total was found in ORAGENICS, INC.'s SEC filings.
Oragenics, Inc. (OGEN) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
$-2.53M
-11.3% vs year-ago quarter
Operating cash flow
$-2.19M
-66.4% vs year-ago quarter
Free cash flow
—
EPS
$-0.57
+81.6% vs year-ago quarter
Dividend per share
None
Shares outstanding
4.51M
+9.3% vs year-ago quarter
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- OGEN (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- FL
- Headquarters
- Lakewood Ranch, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1174940
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$2.6M | -$2.3M | -$2.5M | -$3.1M | -$1.7M |
| Net income | -$2.5M | -$2.2M | -$2.3M | -$3.1M | -$2.3M |
| Diluted EPS | -$0.57 | -$0.51 | -$0.54 | -$1.96 | -$3.10 |
| Operating cash flow | -$2.2M | -$2.2M | -$2.8M | -$3.0M | -$1.3M |
| Total assets | $5.5M | $7.5M | $10.1M | $12.7M | $2.1M |
| Total liabilities | $1.8M | $1.3M | $1.8M | $2.9M | $4.3M |
| Stockholders' equity | $3.7M | $6.2M | $8.3M | $9.8M | -$2.1M |
| Cash and investments | $3.9M | $6.1M | $8.4M | $11.4M | $2.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 16, 2026 | Sep 16, 2026 |
| 8-K |
Current report
Listing notice, Other events
|
Aug 28, 2026 | Aug 26, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, Officer or director change, Shareholder vote results
|
Jul 6, 2026 | Jun 29, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
May 19, 2026 | May 18, 2026 |
| 10-Q | Quarterly report | May 8, 2026 | Mar 31, 2026 |
All 1003 Oragenics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.